Page last updated: 2024-08-21

vancomycin and fidaxomicin

vancomycin has been researched along with fidaxomicin in 166 studies

Research

Studies (166)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (2.41)	29.6817
2010's	117 (70.48)	24.3611
2020's	45 (27.11)	2.80

Authors

Authors	Studies
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP	1
Karlowsky, JA; Laing, NM; Zhanel, GG	1
Byrne, B; Emery, J; Krulicki, W; Louie, TJ; Mah, M	1
Donskey, C; Goldstein, EJ; Louie, T; Miller, M; Mullane, K	1
Babakhani, F; Robert, N; Sears, P; Seddon, J; Shue, YK	1
Biedenbach, DJ; Jones, RN; Putnam, SD; Ross, JE	1
Bremner, JB; Casadei, G; Chen, C; Doll, NK; Kelso, MJ; Lewis, K	1
Artsimovitch, I; Chan, ST; Chu, AJ; Harper, R; Lin, L; Ma, C; Xiao, M; Yang, X; Ye, J; Zuo, Z	1
Chang, M; De Benedetti, S; Fisher, JF; Janardhanan, J; Lastochkin, E; Masitas, C; Mobashery, S; Oliver, AG; Qian, Y; Schroeder, VA; Speri, E; Wang, M; Wolter, WR	1
Poxton, IR	1
Byrne, B; Emery, J; Lawley, B; Louie, T; Munro, K; Tannock, GW; Taylor, C; Young, W	1
Gerding, DN; Johnson, S	2
Dolgin, E	1
Golan, Y; Gorbach, S; Lentnek, A; Louie, TJ; Miller, MA; Mullane, KM; Sears, P; Shue, YK; Weiss, K	1
DuPont, HL	3
Babakhani, F; Gomez, A; Robert, N; Sears, P	1
Craig, WA; Safdar, N	1
Gupta, K; Hermos, JA; Linsky, A	1
Gorbach, S; Mullane, KM	1
Golan, Y; Gorbach, SL; Lentnek, A; Louie, TJ; Miller, MA; Mullane, KM; Sears, PS; Shue, YK; Weiss, K	1
Babakhani, F; Citron, DM; Gerding, DN; Goldstein, EJ; Sambol, SP; Sears, P	1
Morrow, T	1
Vaishnavi, C	2
Bliss, D; Butler, M; Drekonja, DM; Filice, GA; MacDonald, R; Rector, TS; Wilt, TJ	1
Kee, VR	1
Cornely, OA; Crook, DW; Esposito, R; Gorbach, S; Poirier, A; Sears, P; Somero, MS; Weiss, K	1
Wilcox, MH	1
Babakhani, F; Cheknis, A; Gerding, DN; Johnson, S; Kean, Y; Nagaro, K; Petrella, LA; Sambol, SP; Sears, PS	1
Ballard, TE; Guerrant, RL; Hoffman, PS; Kennedy, A; Kolling, GL; Macdonald, TL; Olekhnovich, I; Riggins, M; van Opstal, E; Wang, X; Warren, CA; Warthan, M	1
Crawford, T; Danziger, L; Huesgen, E	1
Gerding, DN; Gorbach, SL; Johnson, S; Louie, TJ; Ruiz, NM	1
Anderson, DJ; Chen, LF	1
Citron, DM; Figueroa, I; Gerding, DN; Goldstein, EJ; Johnson, S; Sambol, SP	1
Allgren, RL; Sellers, S; Weiss, K	1
Crook, DW; Louie, TJ; Miller, MA; Sears, P; Weiss, K	1
Babakhani, F; Donskey, CJ; Miller, MA; Mullane, K; Nerandzic, MM	1
Byrne, B; Cannon, K; Emery, J; Eyben, M; Krulicki, W; Louie, TJ; Ward, L	1
Babakhani, F; Citron, DM; Goldstein, EJ	1
Bauer, MP; Dale, AP; Fawley, WN; Gerding, DN; Gorbach, SL; Hensgens, MP; Kuijper, EJ; Miller, MA; Wilcox, MH	1
Cornely, OA; Crook, DW; Gorbach, SL; Louie, TJ; Miller, MA	1
Babakhani, F; Bouillaut, L; Gomez, A; Nguyen, L; Sears, P; Sonenshein, AL	1
Angus, BJ; Cornely, OA; Crook, DW; Esposito, R; Gorbach, SL; Kean, Y; Louie, TJ; Miller, MA; Peto, TE; Stoesser, NE; Walker, AS; Weiss, K; Young, BC	1
Cornely, OA	1
Allen, CA; Babakhani, F; Nguyen, L; Sears, P; Sorg, JA	1
Guerrant, RL; Hoffman, PS; Kolling, GL; Li, Y; Moore, JH; Riggins, MS; van Opstal, EJ; Warren, CA	1
Babakhani, F; Bouillaut, L; Gomez, A; Sears, P; Sims, C; Sonenshein, AL	1
Arzese, A; Bassetti, M; Pecori, D; Villa, G; Wilcox, M	1
Bauer, MP; Debast, SB; Kuijper, EJ; Sanders, IM; Wilcox, MH	1
Neurath, MF; Strauss, R	1
Cornely, OA; Fantin, B; Gorbach, S; Kean, Y; Miller, MA; Mullane, K	1
Baji, P; Banai, J; Brodszky, V; Gulácsi, L; Kertész, A; Kopcsóné Németh, I; Ludwig, E; Péntek, M; Prinz, G; Reményi, P; Strbák, B; Zsoldiné Urbán, E	1
Cornely, OA; Crook, DW; Golan, Y; Gorbach, SL; Josephson, MA; Louie, TJ; Miller, MA; Mullane, KM	1
Clutter, DS; Dubrovskaya, Y; Merl, MY; Press, R; Safdar, A; Teperman, L	1
Barnes, SW; Leeds, JA; Mullin, S; Ruzin, A; Sachdeva, M	1
Ebigbo, A; Messmann, H	1
Patel, LN; Schairer, J; Shen, B	1
John, E; Lippmann, N; Lübbert, C; Mössner, J; Weis, S	1
Babakhani, F; Crook, DW; Del Ojo Elias, C; Eyre, DW; Gorbach, SL; Griffiths, D; Peto, TE; Seddon, J; Walker, AS	1
Citron, DM; Goldstein, EJ; Tyrrell, KL	1
Bruyère, T; Caspers, P; Keck, W; Knezevic, A; Locher, HH; Pfaff, P; Ritz, D; Schroeder, S	1
Shafran, DM; Shafran, SD	1
Curry, SR; Marsh, JW	1
Collins, SH; D'Agostino, RB; Gorbach, S; Kean, Y; Pencina, KM	1
Miigoć, H; Piekarska, M; Wandałowicz, AD	1
Chen, X; Cheng, M; Hing, TC; Ho, S; Ichikawa, Y; Kelly, CP; Koon, HW; Pothoulakis, C	1
Cornely, OA; Ivanescu, C; Nathwani, D; Odeyemi, IA; Odufowora-Sita, O; Retsa, P	1
Cornely, OA; Nathwani, D; Odeyemi, IA; Odufowora-Sita, O; Retsa, P; Van Engen, AK	1
Belyaev, O; Chromik, AM; Deleites, C; Herzog, T; Uhl, W	1
Leeds, JA; Sachdeva, M	1
Johnson, S; Soriano, MM	1
Keller, JJ; Kuijper, EJ	1
Payne, L; Sattar, A; Thommes, P; Vickers, RJ; Warn, P	1
Biswas, JS; Goldenberg, SD; Newsholme, W; Otter, JA; Patel, A; van Kleef, E; Wade, P	1
Alm, E; Burgess, J; Burns, L; Didyk, E; Edelstein, C; Giovanelli, A; Kassam, Z; Mendolia, G; Noh, A; Smith, M; Stollman, N	1
Marra, F; Ng, K	1
Gademann, K; Hattori, H; Kaufmann, E; Miyatake-Ondozabal, H	1
Doron, S; Gorbach, S; Mizusawa, M	1
Forbes, BA; Gerding, DN; Goldstein, EJ; Jacobus, NV; Jenkins, SG; Johnson, S; McDermott, LA; Mirrett, S; Patel, R; Snydman, DR; Stone, S; Thorpe, C	1
Downham, G; Gallagher, JC; Haynes, K; Navalkele, B; Reilly, JP; Trivedi, M	1
Anguita, P; Cobo Reinoso, J; Gani, R; Grau Cerrato, S; Mensa Pueyo, J; Rubio-Rodríguez, D; Rubio-Terrés, C; Salavert Lletí, M; Toledo, A; Watt, M	1
Clozel, M; Enderlin-Paput, M; Locher, HH; Pfaff, P; Ritz, D; Seiler, P; Weiss, M	1
Freeman, J; Vernon, J; Vickers, R; Wilcox, MH	1
Housman, ST; Kuti, JL; Nicolau, DP; Quintiliani, R; Thabit, AK	1
Alam, MJ; Garey, KW; Khaleduzzaman, M; Nicolau, DP; Thabit, AK	1
Cadnum, JL; Chan, L; Chesnel, L; Deshpande, A; Donskey, CJ; Gao, L; Hurless, K; Kundrapu, S; Polinkovsky, A	1
Alam, MJ; Bassères, E; Chang, L; Endres, BT; Garey, KW; Kakadiaris, IA; Memariani, A; Vickers, RJ	1
Beneš, J; Polívková, S	1
Zar, FA	1
Baumgartner, LJ; Brown, L; Geier, C	1
Stallmach, A	1
Baro, E; Denies, F; Dervaux, B; Galperine, T; Guery, B; Lannoy, D; Lenne, X; Odou, P	1
Evans, CT; Nelson, RL; Suda, KJ	1
Dinh, A; Le Monnier, A; Tilleul, P; Watt, M	1
Bachmann, O; Dersch, P; Solbach, P	1
Cheng, JW; Kong, F; Kudinha, T; Liao, JW; Xiao, M; Xu, YC; Yang, QW; Yu, SY; Zhou, ML	1
Burton, HE; Mitchell, SA; Watt, M	1
Boegli, L; Chesnel, L; deLancey Pulcini, E; Fisher, S; James, GA; Stewart, PS	1
Backo, JL; Broderick, KC; Corvino, FA; Reveles, KR; Zivkovic, M	1
Adomakoh, N; Aguado, JM; Anttila, VJ; Bisnauthsing, K; Cornely, OA; Georgopali, A; Goldenberg, SD; Guery, B; Karas, A; Kazeem, G; Longshaw, C; Menichetti, F; Palacios-Fabrega, JA; Vehreschild, MJGT	1
Gerding, DN	1
Ajami, NJ; Chesnel, L; Cope, JL; Petrosino, JF; Wong, MC	1
Dorr, MB; Dubberke, ER; Ellison, MC; Eves, K; Gerding, DN; Guris, D; Hanson, ME; Kao, D; Kelly, CP; Kumar, PN; Lee, C; Rahav, G; Yacyshyn, B	1
Cornely, OA; De Nigris, E; Goldenberg, SD; McCrea, C; Watt, M	1
Mullish, BH; Williams, HR	1
Abhyankar, S; Clough, L; Ganguly, S; Grauer, D; Lin, T; Mahmoudjafari, Z; McGuirk, J; Prohaska, L; Shune, L; Singh, A	1
Gamo, K; Hashimoto, A; Kato, K; Kusachi, S; Mikamo, H; Miki, T; Oizumi, Y; Takesue, Y; Tateda, K; Toyoshima, J; Yanagihara, K	1
Wilson, A	1
Chalfin, DB; Delgado, D; Fraser, TG; Lam, SW; Neuner, EA	1
Boulos, RA; Pagano, P; Pillar, CM; Shinabarger, DL; Wolfe, C	1
Birchall, S; Corbett, D; Locher, HH; Skinner, K; Thommes, P	1
Cifu, AS; Gupta, A; Khanna, S	1
Fernández Lisón, LC; Malpartida Flores, M; Martín Rizo, L	1
Gentry, CA; Skrepnek, GH; Tieu, JD; Williams, RJ	1
Gentry, CA; Kurdgelashvili, G; Nguyen, PK; Skrepnek, GH; Thind, S; Williams, RJ	1
Dahl Jørgensen, SM; Dahlerup, JF; Erikstrup, C; Hansen, MM; Hvas, CL; Jørgensen, SP; Lemming, L; Storgaard, M	1
Ramesh, MS; Yee, J	1
Adomakoh, N; Cornely, OA; Georgopali, A; Guery, B; Karas, A; Kazeem, G; Vehreschild, MJGT	1
Aguado, JM; Almirante, B; Cobo, J; González Antona Sánchez, E; Grau, S; López Gutiérrez, C; Rubio-Rodríguez, D; Rubio-Terrés, C; Salavert, M	1
Burger, A; Pahwa, AK; Parsons, AS	1
English, M; Fukushima, A; Okumura, H; Shoji, S; Taieb, V	1
Gasbarrini, A; Gisbert, JP; Hold, GL; Malfertheiner, P; Megraud, F; O'Morain, C; Rokkas, T; Tilg, H	1
Atamna, A; Avni, T; Ayada, G; Babitch, T; Ben-Zvi, H; Bishara, J; Hijazi, R	1
Bowman, JA; Utter, GH	1
Kociolek, LK	1
Bosis, S; Bradford, D; Croos-Dabrera, R; Fortuny, C; Incera, E; Kalocsai, K; Korczowski, B; Lazar, S; Melis, J; Petit, A; van Maanen, R; Wolf, J	1
Lacy Smith, K; Mounsey, A; Nickolich, S; Reddy, VC	1
Chan, PKS; Jiang, X; Lee, WH; Ng, SC; You, JHS	1
Malani, PN; Rao, K	1
Aoki, K; Chono, K; Ishii, Y; Konishi, H; Tateda, K; Yamaguchi, T	1
English, M; Okumura, H; Shoji, S; Ueyama, M	1
Boggiano, VL; Smith, KL; Sullivan, MH	1
Abutaleb, NS; Seleem, MN	1
Bickett-Burkhart, K; Chalasani, N; Fischer, M; Gandhi, D; Orman, ES; Phatharacharukul, P; Purpura, RD; Xu, H	1
Benes, J; Capek, V; Krutova, M; Polivkova, S; Sykorova, B	1
Lodise, TP; Lowry, C; Morgenson, D; Patel, N; Shah, V; Stornelli, N	1
Campbell, DL; Gentry, CA; Williams, RJ	1
Coe, K; Reed, EE; Rinaldi, A; Smith, JM; Stevenson, KB	1
Chen, J; Deresinski, S; Gong, CL; Hay, JW; Hitchcock, MM; Holubar, M	1
Addison, B; Addison, RM; Anderson, DJ; Gergen-Teague, MF; Rutala, WA; Sexton, DJ; Turner, NA; Warren, BG; Weber, DJ	1
Barbut, F; Bémer, P; Berger, P; Bessède, E; Camou, F; Cattoir, V; Couzigou, C; Descamps, D; Dinh, A; Gauzit, R; Gourdon, M; Guery, B; Laurans, C; Lavigne, JP; Le Monnier, A; Lechiche, C; Leflon-Guibout, V; Levast, M; Mootien, JY; N'Guyen, Y; Piroth, L; Prazuck, T; Rogeaux, O; Roux, AL; Vachée, A; Vernet Garnier, V; Wallet, F	1
Chiu, CW; Hung, YP; Ko, WC; Lee, CC; Tsai, PJ	1
Alangaden, GJ; Church, B; Davis, SL; Kenney, RM; Wu, T	1
Allerberger, F; Bouza, E; Burns, K; Coia, JE; Fitzpatrick, F; Goorhuis, A; Guery, B; Hristea, A; Krutova, M; Kuijper, EJ; Norén, T; Ooijevaar, RE; Reigadas, E; Scharvik Olesen, BR; Tschudin-Sutter, S; van Prehn, J; van Rossen, TM; Vehreschild, MJGT; Vogelzang, EH; Wilcox, MH	1
Dong, K; Fang, N; Ha, D; Holubar, M; Lee, S; Leung, T; Meng, L	1
Collins, DA; Riley, TV	1
de Meij, TGJ; Drew, RJ; Fitzpatrick, F; Krutova, M; Kuijper, EJ; Wilcox, MH	1
Calais, LA; Climo, MW; Donskey, CJ; Ge, L; Gerding, DN; Goetz, MB; Goldberg, AM; Gordin, FM; Gupta, K; Haegerich, T; Johnson, M; Johnson, N; Johnson, S; Li, X; Reda, DJ; Ringer, R	1
Armiñanzas Castillo, C; Cano Yuste, A; Cobo Reinoso, J; De La Torre Cisneros, J; Díaz Pollán, B; Escudero-Sanchez, R; Fernández Fradejas, J; García Basas, L; García Fernández, S; Giner, L; Gutierrez Rojas, A; Gutiérrez, B; López Medrano, F; Martín Segarra, O; Merino De Lucas, E; Muriel García, A; Olmedo Sampedrio, M; Ramos Martínez, A; Rodríguez Hernández, MJ; Rodríguez-Pardo, D; Ruíz Ruigomez, M; Sáez Bejar, C; Salavert Lletí, M; Tasias Pitarch, M; Valencia Alijo, A	1
Fitzpatrick, F; Safdar, N; Tschudin-Sutter, S; van Prehn, J	1
Enoki, Y; Hasegawa, T; Kunishima, H; Matsumoto, K; Mihara, T; Mikamo, H; Mori, N; Morinaga, Y; Nakamura, A; Ohge, H; Sasaki, M; Shimamura, C; Shimamura, R; Suzuki, H; Suzuki, S; Taguchi, K; Tashiro, S; Yamagishi, Y; Yanagihara, K; Yoshikawa, M; Yoshizawa, S	1
Dai, J; Gong, J; Guo, R	1
Bidell, MR; Molleti, RR; Tatara, AW	1
Gottlieb, M; Long, B	1
Appaneal, HJ; LaPlante, KL; Liao, JX; Vicent, ML; Vyas, A	1
Chuard, C; Meuwly, M	1
Bishop, EJ; Tiruvoipati, R	1
Delbalso, AN; Hitchcock, AM; Kufel, WD; Paolino, KM	1
Beneš, J; Kohout, P; Krůtová, M; Musil, V; Stebel, R; Vejmelka, J	1
Jung, L; Lübbert, C; Schönherr, S	1
Farraye, FA; Hashash, JG; Khanna, S; Koop, AH; Pardi, DS; Travers, PM	1
Castagnola, E; Lo Porto, D; Mularoni, A; Saffioti, C	1
Álvarez-Pérez, S; Anega, B; Blanco, JL; García, ME; Hernández, M	1

Reviews

45 review(s) available for vancomycin and fidaxomicin

Article	Year
Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future microbiology, 2010, Volume: 5, Issue:4 Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Clinical Trials as Topic; Clostridioides difficile; Cross Infection; DNA-Directed RNA Polymerases; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Secondary Prevention; Treatment Outcome; Vancomycin	2010
Management of Clostridium difficile infection: thinking inside and outside the box. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Dec-01, Volume: 51, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitoxins; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Vaccination; Vancomycin	2010
Fidaxomicin: first-in-class macrocyclic antibiotic. Expert review of anti-infective therapy, 2011, Volume: 9, Issue:7 Topics: Actinomycetales; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Cross Infection; DNA-Directed RNA Polymerases; Fidaxomicin; Gastrointestinal Tract; Humans; Microbial Sensitivity Tests; Nucleic Acid Synthesis Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome; Vancomycin	2011
Clostridium difficile infection: clinical spectrum and approach to management. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2011, Volume: 30, Issue:6 Topics: Aminoglycosides; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Dietary Supplements; Digestive System Surgical Procedures; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Fidaxomicin; Humans; Ileus; Immunoglobulins, Intravenous; Inflammatory Bowel Diseases; Metronidazole; Severity of Illness Index; Vancomycin; Withholding Treatment	2011
Comparative effectiveness of Clostridium difficile treatments: a systematic review. Annals of internal medicine, 2011, Dec-20, Volume: 155, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Comparative Effectiveness Research; Diarrhea; Drug Therapy, Combination; Fidaxomicin; Humans; Metronidazole; Recurrence; Vancomycin	2011
Clostridium difficile infection in older adults: a review and update on its management. The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:1 Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Infection Control; Metronidazole; Risk Factors; Vancomycin	2012
Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Jun-01, Volume: 69, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Microbial Sensitivity Tests; Severity of Illness Index; Vancomycin	2012
Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Clinical Trials as Topic; Clostridioides difficile; Clostridium Infections; Diarrhea; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Fidaxomicin; Humans; Treatment Outcome; Vancomycin	2012
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Eosinophils; Feces; Fidaxomicin; Humans; Intention to Treat Analysis; Leukocyte Count; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Vancomycin	2012
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18 Suppl 6 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Recurrence; Vancomycin	2012
Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert review of anti-infective therapy, 2012, Volume: 10, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Risk Factors; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Vancomycin	2012
Diagnosis and management of Clostridium difficile infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:10 Topics: Administration, Oral; Aminoglycosides; Anti-Infective Agents; Biological Therapy; Clostridioides difficile; Clostridium Infections; Colectomy; False Positive Reactions; Fidaxomicin; Humans; Immunotherapy; Metronidazole; Molecular Diagnostic Techniques; Vancomycin	2013
[Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence]. Orvosi hetilap, 2013, Jun-09, Volume: 154, Issue:23 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Cross Infection; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Treatment Outcome; Vancomycin	2013
Treating Clostridium difficile infection. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2014, Apr-15, Volume: 186, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Vaccines; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Probiotics; Randomized Controlled Trials as Topic; Treatment Outcome; Vancomycin	2014
[Clostridium difficile infecion--diagnostics, prevention and treatment]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 36, Issue:214 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Feces; Fidaxomicin; Humans; Metronidazole; Probiotics; Secondary Prevention; Vancomycin	2014
Challenges and opportunities in the management of Clostridium difficile infection. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:8 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Immunologic Factors; Metronidazole; Probiotics; Vancomycin	2014
Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Treatment Outcome; Vancomycin	2014
Treatment of Clostridium difficile infections. Infectious disease clinics of North America, 2015, Volume: 29, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Administration Schedule; Drug Therapy, Combination; Fidaxomicin; Gastrointestinal Diseases; Humans; Metronidazole; Nitro Compounds; Randomized Controlled Trials as Topic; Recurrence; Rifamycins; Rifaximin; Thiazoles; Vancomycin	2015
Treatment of recurrent and severe Clostridium difficile infection. Annual review of medicine, 2015, Volume: 66 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Humans; Metronidazole; Microbiota; Recurrence; Severity of Illness Index; Transplantation; Vancomycin	2015
Fidaxomicin--the new drug for Clostridium difficile infection. The Indian journal of medical research, 2015, Volume: 141, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Fidaxomicin; Humans; Recurrence; Vancomycin	2015
Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs, 2015, Volume: 75, Issue:10 Topics: Aminoglycosides; Anti-Bacterial Agents; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplantation; Fidaxomicin; Humans; Incidence; Metronidazole; Molecular Diagnostic Techniques; Polymerase Chain Reaction; Probiotics; Recurrence; Risk Factors; Vancomycin	2015
Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. Drugs & aging, 2015, Volume: 32, Issue:8 Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Fidaxomicin; Humans; Metronidazole; Recurrence; Risk Factors; Vancomycin	2015
Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. The Cochrane database of systematic reviews, 2017, 03-03, Volume: 3 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bacitracin; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Randomized Controlled Trials as Topic; Teicoplanin; Treatment Outcome; Vancomycin	2017
[Individualized treatment strategies for Clostridium difficile infections]. Der Internist, 2017, Volume: 58, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplantation; Female; Fidaxomicin; Humans; Metronidazole; Recurrence; Secondary Prevention; Vancomycin	2017
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. PharmacoEconomics, 2017, Volume: 35, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridium Infections; Cost-Benefit Analysis; Drug Costs; Fidaxomicin; Hospitalization; Humans; Metronidazole; Recurrence; Vancomycin	2017
Clinical medicine (London, England), 2018, Volume: 18, Issue:3 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplantation; Fidaxomicin; Humans; Metronidazole; Probiotics; Vancomycin	2018
Antibiotic Treatment for Clostridium difficile Infection in Adults. The American journal of nursing, 2018, Volume: 118, Issue:7 Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Fidaxomicin; Humans; Vancomycin	2018
Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting. Infection control and hospital epidemiology, 2018, Volume: 39, Issue:8 Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Fidaxomicin; Health Care Costs; Humans; Monte Carlo Method; Quality-Adjusted Life Years; Recurrence; Vancomycin	2018
Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease. Advances in chronic kidney disease, 2019, Volume: 26, Issue:1 Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimicrobial Stewardship; Broadly Neutralizing Antibodies; Clostridium Infections; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplantation; Fidaxomicin; Hand Hygiene; Health Care Costs; Humans; Infection Control; Kidney Failure, Chronic; Length of Stay; Metronidazole; Patient Isolation; Renal Insufficiency, Chronic; Secondary Prevention; Vancomycin	2019
Clinical Guideline Highlights for the Hospitalist: Diagnosis and Management of Clostridium difficile in Adults. Journal of hospital medicine, 2020, 02-01, Volume: 15, Issue:2 Topics: Adult; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Hospitalists; Humans; Practice Guidelines as Topic; Vancomycin	2020
Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020, Volume: 26, Issue:1 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Recurrence; Treatment Outcome; Vancomycin	2020
A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent United European gastroenterology journal, 2019, Volume: 7, Issue:8 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Combined Modality Therapy; Fecal Microbiota Transplantation; Female; Fidaxomicin; Humans; Middle Aged; Network Meta-Analysis; Placebos; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Vancomycin	2019
Evolving Strategies to Manage Clostridium difficile Colitis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020, Volume: 24, Issue:2 Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Bacterial Toxins; Broadly Neutralizing Antibodies; Clostridioides difficile; Colectomy; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplantation; Fidaxomicin; Humans; Ileostomy; Risk Factors; Therapeutic Irrigation; Vancomycin	2020
Clostridioides difficile Infection: Update on Management. American family physician, 2020, 02-01, Volume: 101, Issue:3 Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Child; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Infant; Practice Guidelines as Topic; Risk Factors; Severity of Illness Index; Vancomycin	2020
Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA, 2020, Apr-14, Volume: 323, Issue:14 Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Feces; Fidaxomicin; Humans; Nucleic Acid Amplification Techniques; Practice Guidelines as Topic; Vancomycin	2020
Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability? Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2021, Volume: 54, Issue:6 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Development; Fidaxomicin; Recurrence; Secondary Prevention; Spores, Bacterial; Vancomycin	2021
Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-31, Volume: 75, Issue:3 Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Hospitals; Humans; Patient Discharge; Vancomycin	2022
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Letters in applied microbiology, 2022, Volume: 75, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Benzimidazoles; Clostridioides; Clostridioides difficile; Clostridium; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Pyridines; Vancomycin	2022
How to: Clostridioides difficile infection in children. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:8 Topics: Aged; Anti-Bacterial Agents; Child; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Vancomycin	2022
How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed? The Lancet. Infectious diseases, 2022, Volume: 22, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Vancomycin	2022
Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022, Volume: 28, Issue:11 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Randomized Controlled Trials as Topic; Vancomycin	2022
Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis. European journal of clinical pharmacology, 2022, Volume: 78, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridium Infections; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Vancomycin	2022
Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Pharmacotherapy, 2022, Volume: 42, Issue:11 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Middle Aged; Recurrence; Vancomycin	2022
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. The Journal of antimicrobial chemotherapy, 2022, 12-23, Volume: 78, Issue:1 Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Vancomycin	2022
Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient. Transplant infectious disease : an official journal of the Transplantation Society, 2023, Volume: 25 Suppl 1 Topics: Adult; Anti-Bacterial Agents; Child; Clostridium Infections; Diarrhea; Fidaxomicin; Hematopoietic Stem Cell Transplantation; Humans; Transplant Recipients; Vancomycin	2023

Trials

28 trial(s) available for vancomycin and fidaxomicin

Article	Year
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Anti-Bacterial Agents; Bacteroides; Clostridioides difficile; Clostridium Infections; Dose-Response Relationship, Drug; Glycosides; Humans; Vancomycin	2009
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycosides; Humans; Male; Middle Aged; Treatment Outcome	2009
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading, England), 2010, Volume: 156, Issue:Pt 11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; DNA, Bacterial; Feces; Fidaxomicin; Humans; Intestines; Metagenome; Phylogeny; Vancomycin	2010
Fidaxomicin versus vancomycin for Clostridium difficile infection. The New England journal of medicine, 2011, Feb-03, Volume: 364, Issue:5 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Enterocolitis, Pseudomembranous; Feces; Female; Fidaxomicin; Humans; Intention to Treat Analysis; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Secondary Prevention; Treatment Outcome; Vancomycin	2011
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Male; Prohibitins; Vancomycin	2011
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:4 Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Double-Blind Method; Enterocolitis, Pseudomembranous; Feces; Female; Fidaxomicin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Vancomycin	2012
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Female; Fidaxomicin; Humans; Male; Middle Aged; Molecular Typing; Polymorphism, Restriction Fragment Length; Prohibitins; Recurrence; Treatment Outcome; Vancomycin	2012
Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies. Future microbiology, 2012, Volume: 7, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Fidaxomicin; Humans; Male; Middle Aged; Secondary Prevention; Treatment Outcome; Vancomycin	2012
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Canada; Clostridioides difficile; Clostridium Infections; Diarrhea; DNA, Bacterial; Enterotoxins; Europe; Feces; Fidaxomicin; Humans; Middle Aged; Prohibitins; Secondary Prevention; Time Factors; United States; Vancomycin	2012
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Administration, Oral; Aged; Aminoglycosides; Anti-Bacterial Agents; Chromatography, Liquid; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Feces; Female; Fidaxomicin; Humans; Male; Middle Aged; Severity of Illness Index; Tandem Mass Spectrometry; Treatment Outcome; Vancomycin	2012
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Canada; Candida; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Drug Resistance, Bacterial; Enterococcus; Feces; Female; Fidaxomicin; Humans; Incidence; Limit of Detection; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Outcome; United States; Vancomycin	2012
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Load; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Cytotoxins; DNA, Bacterial; Double-Blind Method; Feces; Fidaxomicin; Gene Expression Regulation, Bacterial; Humans; Intestines; Limit of Detection; Metagenome; Real-Time Polymerase Chain Reaction; RNA, Ribosomal, 16S; Secondary Prevention; Vancomycin	2012
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Canada; Clostridioides difficile; Clostridium Infections; Confidence Intervals; Double-Blind Method; Europe; Feces; Female; Fidaxomicin; Humans; Kaplan-Meier Estimate; Male; Metronidazole; Middle Aged; Secondary Prevention; Time Factors; Treatment Outcome; United States; Vancomycin; Young Adult	2012
Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Double-Blind Method; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Secondary Prevention; Treatment Outcome; Vancomycin	2013
[Challenges of Clostridium difficile infection]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2013, Volume: 108, Issue:8 Topics: Aminoglycosides; Biodiversity; Cause of Death; Colonoscopy; Cross Infection; Disinfection; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Hospital Mortality; Humans; Metronidazole; Patient Readmission; Prognosis; Recurrence; Tomography, X-Ray Computed; Transplantation; Vancomycin	2013
Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. The Journal of infectious diseases, 2014, May-01, Volume: 209, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Fidaxomicin; Genome, Bacterial; Humans; Polymorphism, Single Nucleotide; Secondary Prevention; Sequence Analysis, DNA; Vancomycin	2014
Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10 Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Creatine; Female; Fidaxomicin; Humans; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Recurrence; Risk Factors; Vancomycin; Young Adult	2014
Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. The Journal of hospital infection, 2015, Volume: 90, Issue:3 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Environmental Microbiology; Female; Fidaxomicin; Hospitalization; Humans; Male; Metronidazole; Vancomycin	2015
Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infection control and hospital epidemiology, 2016, Volume: 37, Issue:2 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Colony Count, Microbial; Connecticut; Enterocolitis, Pseudomembranous; Feces; Female; Fidaxomicin; Humans; Male; Middle Aged; Polymerase Chain Reaction; Vancomycin	2016
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. The Lancet. Infectious diseases, 2018, Volume: 18, Issue:3 Topics: Aged; Aged, 80 and over; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Male; Middle Aged; Vancomycin	2018
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 08-16, Volume: 67, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplantation; Female; Fidaxomicin; Humans; Male; Metronidazole; Middle Aged; Patient Readmission; Recurrence; Risk Factors; Secondary Prevention; Vancomycin; Young Adult	2018
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness. The Journal of antimicrobial chemotherapy, 2018, 09-01, Volume: 73, Issue:9 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridium Infections; Cost-Benefit Analysis; England; Female; Fidaxomicin; Humans; Male; Middle Aged; Quality of Life; Recurrence; Treatment Outcome; Vancomycin	2018
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2018, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Female; Fidaxomicin; Hospitalization; Humans; Japan; Male; Middle Aged; Recurrence; Secondary Prevention; Treatment Outcome; Vancomycin; Young Adult	2018
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Gastroenterology, 2019, Volume: 156, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Denmark; Fecal Microbiota Transplantation; Female; Fidaxomicin; Humans; Male; Middle Aged; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vancomycin; Young Adult	2019
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Feces; Female; Fidaxomicin; Follow-Up Studies; Humans; Male; Middle Aged; Recurrence; Ribotyping; Treatment Outcome; Vancomycin	2019
Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-17, Volume: 71, Issue:10 Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Child; Child, Preschool; Clostridioides; Clostridioides difficile; Clostridium; Clostridium Infections; Fidaxomicin; Humans; Single-Blind Method; Treatment Outcome; Vancomycin	2020
Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 03-01, Volume: 74, Issue:4 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Clostridioides; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Prospective Studies; Vancomycin	2022
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence. Contemporary clinical trials, 2022, Volume: 116 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; COVID-19; Diarrhea; Fidaxomicin; Humans; Recurrence; Treatment Outcome; Vancomycin	2022

Other Studies

93 other study(ies) available for vancomycin and fidaxomicin

Article	Year
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States	2007
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests	2008
Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Agar; Aminoglycosides; Anti-Bacterial Agents; Cations; Clostridioides difficile; Colony Count, Microbial; Culture Media; Enterocolitis, Pseudomembranous; Fidaxomicin; Glycosides; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Microbial Sensitivity Tests	2010
In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Fidaxomicin; Humans; In Vitro Techniques; Staphylococcus	2010
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells. Bioorganic & medicinal chemistry letters, 2014, Jan-15, Volume: 24, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Cycle; Cell Line; Clostridioides difficile; Fidaxomicin; Humans; Hydrazones; Microbial Sensitivity Tests	2014
Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction. European journal of medicinal chemistry, 2020, Dec-15, Volume: 208 Topics: Animals; Bacteria; Bacterial Proteins; Benzoates; Benzophenones; Benzyl Compounds; DNA-Directed RNA Polymerases; Microbial Sensitivity Tests; Microsomes, Liver; Protein Binding; Rats; Sigma Factor	2020
Structure-Activity Relationship for the Picolinamide Antibacterials that Selectively Target ACS medicinal chemistry letters, 2021, Jun-10, Volume: 12, Issue:6 Topics:	2021
'Game changer' antibiotic and others in works for superbug. Nature medicine, 2011, Volume: 17, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Secondary Prevention; Streptococcal Infections; United States; United States Food and Drug Administration; Vancomycin	2011
The search for effective treatment of Clostridium difficile infection. The New England journal of medicine, 2011, Feb-03, Volume: 364, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Secondary Prevention; Vancomycin	2011
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 8 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Fidaxomicin; Microbial Sensitivity Tests; Time Factors; Vancomycin	2011
Fidaxomicin for Clostridium difficile Infection. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Enterotoxins; Fidaxomicin; Humans; Secondary Prevention; Vancomycin	2011
Fidaxomicin for Clostridium difficile infection. The New England journal of medicine, 2011, 05-12, Volume: 364, Issue:19 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Proton Pump Inhibitors; Secondary Prevention; Vancomycin	2011
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Male; Middle Aged; Vancomycin; Young Adult	2011
Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin. Managed care (Langhorne, Pa.), 2011, Volume: 20, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Comparative Effectiveness Research; Cost-Benefit Analysis; Fidaxomicin; Humans; Secondary Prevention; Vancomycin	2011
Progress with a difficult infection. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Male; Vancomycin	2012
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Benzamides; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Enzyme Inhibitors; Fidaxomicin; Mice; Microbial Sensitivity Tests; Nitro Compounds; Pyruvate Synthase; Thiazoles; Treatment Outcome; Vancomycin	2012
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Diarrhea; Endpoint Determination; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Polymers; Sulfonic Acids; Treatment Outcome; Vancomycin	2012
Antimicrobial activities of fidaxomicin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials as Topic; Clostridioides difficile; Clostridium Infections; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Feces; Fidaxomicin; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Recurrence; Vancomycin	2012
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Confidence Intervals; Creatine; Fever; Fidaxomicin; Humans; Leukocyte Count; Leukocytosis; Odds Ratio; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Renal Insufficiency; ROC Curve; Severity of Illness Index; Time Factors; Treatment Failure; Vancomycin	2012
Fidaxomicin inhibits spore production in Clostridium difficile. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Load; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Gene Expression Regulation, Bacterial; Genes, Bacterial; Metronidazole; Microbial Sensitivity Tests; Rifamycins; Rifaximin; Spores, Bacterial; Vancomycin	2012
Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Administration Schedule; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Male; Recurrence; Treatment Outcome; Vancomycin	2013
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Culture Media; Fidaxomicin; Microbial Sensitivity Tests; Spores, Bacterial; Taurocholic Acid; Vancomycin	2013
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:2 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteroides; Cecum; Clostridioides difficile; Clostridium Infections; DNA, Bacterial; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Intestines; Male; Metronidazole; Mice; Mice, Inbred C57BL; Nitro Compounds; Recurrence; Thiazoles; Treatment Outcome; Vancomycin	2013
Fidaxomicin inhibits toxin production in Clostridium difficile. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Culture Media; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Fidaxomicin; Gene Expression; Gene Expression Profiling; Humans; Metronidazole; Vancomycin	2013
Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Enterocolitis, Pseudomembranous; Europe; Fidaxomicin; Humans; Metronidazole; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymerase Chain Reaction; Ribotyping; Thiazoles; Treatment Outcome; Vancomycin	2013
[Clostridium difficile infections - still a major challenge]. MMW Fortschritte der Medizin, 2013, Apr-18, Volume: 155, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Colectomy; Combined Modality Therapy; Cross Infection; Disease Notification; Enterocolitis, Pseudomembranous; Fidaxomicin; Metronidazole; Probiotics; Vancomycin; Virulence	2013
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. American journal of nephrology, 2013, Volume: 38, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Treatment Outcome; Vancomycin; Young Adult	2013
Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:9 Topics: Adult; Aged; Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Clinical Trials as Topic; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Hematopoietic Stem Cell Transplantation; Humans; Male; Metronidazole; Middle Aged; Organ Transplantation; Survival Analysis; Treatment Outcome; Vancomycin; Vancomycin Resistance	2013
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Wall; Clostridioides difficile; DNA Mutational Analysis; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Fidaxomicin; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Thiazoles; Vancomycin	2014
Fecal transplantation therapy for Clostridium difficile-associated pouchitis. International journal of colorectal disease, 2014, Volume: 29, Issue:2 Topics: Adult; Aminoglycosides; Child; Clostridioides difficile; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Humans; Male; Pouchitis; Rifamycins; Rifaximin; Vancomycin	2014
[Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?]. Zentralblatt fur Chirurgie, 2014, Volume: 139, Issue:4 Topics: Aminoglycosides; Clostridioides difficile; Colectomy; Colostomy; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Enterocolitis, Pseudomembranous; Feces; Fidaxomicin; Germany; Humans; Incidence; Metronidazole; Recurrence; Transplantation; Vancomycin	2014
Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium; Cluster Analysis; Fidaxomicin; Metronidazole; Microbial Sensitivity Tests; RNA, Ribosomal, 16S; Species Specificity; Vancomycin	2014
Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fidaxomicin; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Oxazolidinones; Protein Biosynthesis; Recombinant Proteins; RNA; Subcellular Fractions; Transcription, Genetic; Vancomycin	2014
Therapeutic approaches for Clostridium difficile infections. Current protocols in microbiology, 2013, Oct-02, Volume: 30 Topics: Aminoglycosides; Anti-Infective Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitoxins; Bacterial Vaccines; Biological Therapy; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Therapy; Fidaxomicin; Humans; Immunotherapy; Metronidazole; Vancomycin	2013
Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Toxins; Clostridioides difficile; Edema; Enterocolitis, Pseudomembranous; Enterotoxins; Epithelial Cells; Fibroblasts; Fidaxomicin; Gene Expression; Ileum; Injections, Intralesional; Interleukin-1beta; Intestinal Mucosa; Male; Metronidazole; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; RNA, Messenger; Vancomycin	2014
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Fidaxomicin; Humans; Markov Chains; Vancomycin	2014
[Clostridium difficile in visceral surgery]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2015, Volume: 86, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Cohort Studies; Cross Infection; Cross-Sectional Studies; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Fidaxomicin; Germany; Hospital Mortality; Humans; Incidence; Intensive Care Units; Male; Metronidazole; Middle Aged; Minocycline; Patient Readmission; Retrospective Studies; Survival Rate; Tigecycline; Vancomycin; Young Adult	2015
Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2 Topics: Aminoglycosides; Clostridioides difficile; Fidaxomicin; Metronidazole; Microbial Sensitivity Tests; Thiazoles; Vancomycin	2015
SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Benzimidazoles; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Fidaxomicin; Gastrointestinal Tract; Mesocricetus; Microbial Sensitivity Tests; Plasma; Pyridines; Recurrence; Survival Analysis; Treatment Outcome; Vancomycin	2015
Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. The American journal of gastroenterology, 2015, Volume: 110, Issue:4 Topics: Abdominal Pain; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Biological Therapy; Capsules; Clostridioides difficile; Colonoscopy; Diarrhea; Drug Administration Schedule; Enterocolitis, Pseudomembranous; Feces; Female; Fidaxomicin; Freezing; Humans; Irritable Bowel Syndrome; Male; Metronidazole; Microbiota; Recurrence; Transplantation, Homologous; Treatment Outcome; Vancomycin	2015
Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin. Organic letters, 2015, Jul-17, Volume: 17, Issue:14 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Glycosylation; Macrolides; Molecular Structure; Vancomycin	2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Clindamycin; Clostridioides difficile; Diarrhea; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Fluoroquinolones; Genes, Bacterial; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Multiplex Polymerase Chain Reaction; Prohibitins; Sentinel Surveillance; United States; Vancomycin	2015
Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:11 Topics: Aminoglycosides; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Retrospective Studies; Vancomycin	2015
Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Diarrhea; Fidaxomicin; Humans; Kidney Diseases; Neoplasms; Quality-Adjusted Life Years; Spain; Treatment Outcome; Vancomycin	2015
Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Clostridioides difficile; Colony Count, Microbial; Diarrhea; Enterocolitis, Pseudomembranous; Fidaxomicin; Intestines; Metronidazole; Mice; Microbial Sensitivity Tests; Oxazolidinones; Streptococcal Infections; Treatment Outcome; Vancomycin; Vancomycin Resistance; Vancomycin-Resistant Enterococci	2016
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Benzimidazoles; Ceftriaxone; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Fidaxomicin; Fluoroquinolones; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Phenotype; Pyridines; Ribotyping; Vancomycin	2016
A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Annals of clinical microbiology and antimicrobials, 2016, Apr-12, Volume: 15 Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Feces; Female; Fidaxomicin; Humans; Male; Middle Aged; Pilot Projects; Vancomycin	2016
Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:7 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteroides Infections; beta-Lactamases; Clostridium; Feces; Female; Fidaxomicin; Firmicutes; Intestines; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Real-Time Polymerase Chain Reaction; Vancomycin; Vancomycin-Resistant Enterococci	2016
A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe, 2016, Volume: 40 Topics: Agar; Aminoglycosides; Anti-Bacterial Agents; Cell Wall; Clostridioides difficile; Culture Media; Fidaxomicin; Metronidazole; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Optical Imaging; Vancomycin	2016
[Antibiotic treatment of clostridial colitis]. Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne, 2016,Winter, Volume: 65, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Metronidazole; Recurrence; Vancomycin	2016
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence. Annals of internal medicine, 2016, 07-19, Volume: 165, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Nucleic Acid Amplification Techniques; Secondary Prevention; Vancomycin	2016
Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function. Journal of pharmacy practice, 2017, Volume: 30, Issue:6 Topics: Administration, Oral; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Hypersensitivity; Fidaxomicin; Humans; Kidney; Male; Middle Aged; Treatment Outcome; Vancomycin	2017
[Clostridium difficile infection : What is currently available for treatment?] Der Internist, 2016, Volume: 57, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Evidence-Based Medicine; Fidaxomicin; Humans; Megacolon, Toxic; Metronidazole; Treatment Outcome; Vancomycin	2016
Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PloS one, 2017, Volume: 12, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Community-Acquired Infections; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplantation; Fidaxomicin; France; Health Care Costs; Humans; Models, Economic; Quality-Adjusted Life Years; Recurrence; Vancomycin	2017
Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of medical economics, 2017, Volume: 20, Issue:7 Topics: Age Factors; Aminoglycosides; Anti-Bacterial Agents; Clostridium Infections; Cost-Benefit Analysis; Drug Costs; Fidaxomicin; France; Hospitalization; Humans; Markov Chains; Models, Economic; Neoplasms; Randomized Controlled Trials as Topic; Recurrence; Renal Insufficiency; Severity of Illness Index; Vancomycin	2017
High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2018, Volume: 51, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; China; Clostridioides difficile; Clostridium Infections; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fidaxomicin; Fluoroquinolones; Genes, Bacterial; Hospitals, Teaching; Hospitals, University; Humans; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Tigecycline; Vancomycin	2018
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment. The Journal of antimicrobial chemotherapy, 2018, Jan-01, Volume: 73, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Biological Transport; Clostridioides difficile; Colony Count, Microbial; Fidaxomicin; Humans; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Peptides, Cyclic; Spores, Bacterial; Vancomycin	2018
Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation. Pharmacotherapy, 2017, Volume: 37, Issue:12 Topics: Aminoglycosides; Clostridium Infections; Cost Savings; Diarrhea; Fidaxomicin; Health Care Costs; Hospitalization; Humans; Models, Economic; Vancomycin	2017
Is pulsed dosing the answer to treatment of Clostridium difficile infection? The Lancet. Infectious diseases, 2018, Volume: 18, Issue:3 Topics: Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Vancomycin	2018
Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:5 Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Disease Models, Animal; Feces; Female; Fidaxomicin; Gastrointestinal Microbiome; Mice; Mice, Inbred C57BL; RNA, Ribosomal, 16S; Vancomycin	2018
Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:4 Topics: Acute Disease; Administration, Oral; Adult; Aged; Allografts; Clostridioides difficile; Clostridium Infections; Female; Fidaxomicin; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Vancomycin	2018
Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution. Diagnostic microbiology and infectious disease, 2018, Volume: 92, Issue:3 Topics: Anti-Bacterial Agents; Benzoates; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fidaxomicin; Humans; Inhibitory Concentration 50; Metronidazole; Microbial Sensitivity Tests; Stilbenes; Vancomycin	2018
Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile. Journal of medical microbiology, 2018, Volume: 67, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Kinetics; Microbial Sensitivity Tests; Oxazolidinones; Ribotyping; Vancomycin	2018
Diagnosis and Treatment of Clostridium difficile Infection. JAMA, 2018, Sep-11, Volume: 320, Issue:10 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Child; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplantation; Fidaxomicin; Humans; Nucleic Acid Amplification Techniques; Practice Guidelines as Topic; Recurrence; Vancomycin	2018
Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients. Medicina clinica, 2019, 10-11, Volume: 153, Issue:7 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Colonic Neoplasms; Diarrhea; Female; Fidaxomicin; Hematologic Neoplasms; Humans; Male; Metronidazole; Middle Aged; Treatment Outcome; Vancomycin	2019
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection. Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridium Infections; Female; Fidaxomicin; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Recurrence; Retrospective Studies; Treatment Failure; Treatment Outcome; Vancomycin	2019
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019, Volume: 25, Issue:8 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Databases, Factual; Disease Management; Female; Fidaxomicin; Humans; Male; Middle Aged; Propensity Score; Recurrence; Retrospective Studies; Severity of Illness Index; Treatment Outcome; United States; Vancomycin	2019
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Fidaxomicin; Health Care Costs; Humans; Middle Aged; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Spain; Treatment Outcome; Vancomycin	2019
Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020, Volume: 90 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Female; Fidaxomicin; Hospitalization; Humans; Immunocompromised Host; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Risk Factors; Vancomycin	2020
Moving the Needle on Clostridioides difficile Research in Children: A Major Step Forward but Challenges Remain. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-17, Volume: 71, Issue:10 Topics: Adolescent; Child; Clostridioides; Clostridium; Clostridium Infections; Fidaxomicin; Humans; Single-Blind Method; Vancomycin	2020
Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9 Topics: Antibodies, Monoclonal; Broadly Neutralizing Antibodies; Clostridium Infections; Cost-Benefit Analysis; Costs and Cost Analysis; Fecal Microbiota Transplantation; Fidaxomicin; Health Personnel; Hong Kong; Humans; Inflammatory Bowel Diseases; Public Health; Quality-Adjusted Life Years; Recurrence; Treatment Outcome; Vancomycin	2020
The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020, Volume: 26, Issue:5 Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Feces; Fidaxomicin; Gastrointestinal Microbiome; Humans; Mice; Microbiota; RNA, Ribosomal, 16S; Vancomycin	2020
Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2020, Volume: 26, Issue:6 Topics: Aged; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Drug Costs; Drug Utilization Review; Female; Fidaxomicin; Humans; Japan; Length of Stay; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Vancomycin	2020
Management of difficult-to-treat BMJ case reports, 2020, Mar-29, Volume: 13, Issue:3 Topics: Administration, Intravenous; Anti-Bacterial Agents; Clostridium Infections; Colitis; Combined Modality Therapy; Drug Resistance, Multiple, Bacterial; Fecal Microbiota Transplantation; Fidaxomicin; Foot; Humans; Male; Metronidazole; Middle Aged; Osteomyelitis; Vancomycin	2020
Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Scientific reports, 2020, 05-07, Volume: 10, Issue:1 Topics: Animals; Anti-Bacterial Agents; Arthritis, Rheumatoid; Auranofin; Clostridioides difficile; Clostridium Infections; Cross Infection; Drug Repositioning; Fidaxomicin; Gastrointestinal Tract; Humans; Mice; Microbial Sensitivity Tests; Recurrence; Vancomycin	2020
Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis. Clinical and translational gastroenterology, 2020, Volume: 11, Issue:7 Topics: Aged; Anti-Bacterial Agents; Clostridioides; Clostridium Infections; Comorbidity; Diagnostic Errors; Female; Fidaxomicin; Humans; Incidence; Lactulose; Laxatives; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Patient Readmission; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Treatment Failure; Vancomycin	2020
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 103 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cohort Studies; Female; Fidaxomicin; Hospitalization; Humans; Logistic Models; Male; Metronidazole; Middle Aged; Recurrence; Treatment Outcome; Vancomycin	2021
Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile. Pharmacotherapy, 2021, Volume: 41, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Female; Fidaxomicin; Hospitals, Veterans; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vancomycin	2021
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study. International journal of antimicrobial agents, 2021, Volume: 57, Issue:3 Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Utilization; Female; Fidaxomicin; Humans; Male; Metronidazole; Middle Aged; Practice Guidelines as Topic; Recurrence; Retrospective Studies; Risk Factors; Treatment Outcome; Vancomycin	2021
Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile. Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Clostridium Infections; Comorbidity; Drug Administration Routes; Female; Fidaxomicin; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Vancomycin	2021
Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27, Issue:10 Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Cost-Benefit Analysis; Fidaxomicin; Humans; United States; Vancomycin	2021
A prospective, observational study of fidaxomicin use for The Journal of international medical research, 2021, Volume: 49, Issue:6 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides; Clostridioides difficile; Clostridium Infections; Fidaxomicin; France; Humans; Prospective Studies; Vancomycin	2021
Outcomes of clinical decision support for outpatient management of Infection control and hospital epidemiology, 2022, Volume: 43, Issue:10 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Decision Support Systems, Clinical; Female; Fidaxomicin; Humans; Male; Metronidazole; Middle Aged; Outpatients; Vancomycin	2022
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021, Volume: 27 Suppl 2 Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Broadly Neutralizing Antibodies; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Practice Guidelines as Topic; Recurrence; Societies, Medical; Vancomycin	2021
Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study. The Journal of antimicrobial chemotherapy, 2022, 06-29, Volume: 77, Issue:7 Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Broadly Neutralizing Antibodies; Clostridium Infections; Cohort Studies; Fidaxomicin; Humans; Recurrence; Retrospective Studies; Treatment Outcome; Vancomycin	2022
Fidaxomicin-Associated Hypersensitivity Reactions: Report of a Morbilliform Drug Eruption. Journal of pharmacy practice, 2023, Volume: 36, Issue:4 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Eruptions; Exanthema; Female; Fidaxomicin; Humans; Hypersensitivity; Middle Aged; Pharmaceutical Preparations; Vancomycin	2023
Oral fidaxomicin versus vancomycin for Clostridioides difficile infection. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2022, Volume: 29, Issue:12 Topics: Anti-Bacterial Agents; Clostridium Infections; Fidaxomicin; Humans; Vancomycin	2022
[Clostridioides difficile infection: various therapeutic approaches]. Revue medicale suisse, 2022, Oct-12, Volume: 18, Issue:799 Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Vancomycin	2022
Evaluation of fidaxomicin use in patients with a macrolide allergy/intolerance. The Journal of antimicrobial chemotherapy, 2023, 04-03, Volume: 78, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridium Infections; Fidaxomicin; Humans; Hypersensitivity; Macrolides; Vancomycin	2023
[Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile]. Klinicka mikrobiologie a infekcni lekarstvi, 2022, Volume: 28, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides; Clostridioides difficile; Clostridium Infections; Colitis; Czech Republic; Fidaxomicin; Humans; Tigecycline; Vancomycin	2022
[Clostridioides difficile - New Insights and Therapy Recommendations]. Deutsche medizinische Wochenschrift (1946), 2023, Volume: 148, Issue:12 Topics: Aged; Anti-Bacterial Agents; Clostridioides; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Vancomycin	2023
Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease. Journal of gastroenterology and hepatology, 2023, Volume: 38, Issue:11 Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Female; Fidaxomicin; Humans; Inflammatory Bowel Diseases; Male; Recurrence; Retrospective Studies; Treatment Outcome; Vancomycin	2023
In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats. BMC veterinary research, 2023, Nov-16, Volume: 19, Issue:1 Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Clindamycin; Clostridioides difficile; Clostridium Infections; Clostridium perfringens; Diarrhea; Dog Diseases; Dogs; Erythromycin; Fidaxomicin; Humans; Imipenem; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Vancomycin	2023